Page 40 - 80_01

SREBP-­-1c,
ChREBP
y
LXR…

conocimiento
de
la
interrelación
funcional
de
todos
los
FT
implicados
en
la

regulación
de
los
factores
que
afectan
al
HGNA;
y
el
desarrollo
de
agonistas

selectivos,
sin
efectos
secundarios,
que
puedan
tener
efectos
terapéuticos

específicos
sobre
el
HGNA
y
su
progresión
a
la
EHNA.

REFERENCIAS

1. Farrell,
G.C.,
Larter,
C.Z.,
2006.
Nonalcoholic
fatty
liver
disease:
from
steatosis
to
cirrhosis.

Hepatology
43,
S99-­-S112.

2. Angulo,
P.,
2002.
Nonalcoholic
fatty
liver
disease.
N
Engl
J
Med
346,
1221-­-1231.

3. Ludwig,
J.,
Viggiano,
T.R.,
McGill,
D.B.,
Oh,
B.J.,
1980.
Nonalcoholic
steatohepatitis:
Mayo

Clinic
experiences
with
a
hitherto
unnamed
disease.
Mayo
Clin
Proc
55,
434-­-438.

4. Kopec,
K.L.,
Burns,
D.,
2011.
Nonalcoholic
fatty
liver
disease:
a
review
of
the
spectrum
of

disease,
diagnosis,
and
therapy.
Nutr
Clin
Pract
26,
565-­-576.

5. Adams,
L.A.,
Lindor,
K.D.,
2007.
Nonalcoholic
fatty
liver
disease.
Ann
Epidemiol
17,
863-­-

869.

6. Marchesini,
G.,
Babini,
M.,
2006.
Nonalcoholic
fatty
liver
disease
and
the
metabolic

syndrome.
Minerva
Cardioangiol
54,
229-­-239.

7. Edens,
M.A.,
Kuipers,
F.,
Stolk,
R.P.,
2009.
Non-­-alcoholic
fatty
liver
disease
is
associated

with
cardiovascular
disease
risk
markers.
Obes
Rev
10,
412-­-419.

8. Caballería,
L.,
Pera,
G.,
Auladell,
M.A.
y
col.
2010.
Prevalence
and
factors
associated
with

the
presence
of
nonalcoholic
fatty
liver
disease
in
an
adult
population
in
Spain.
Eur
J

Gastroenterol
Hepatol
22,
24-­-32.

9. Bellentani,
S.,
Scaglioni,
F.,
Marino,
M.,
Bedogni,
G.,
2010.
Epidemiology
of
non-­-alcoholic

fatty
liver
disease.
Dig
Dis
28,
155-­-161.

10. Baumeister,
S.E.,
Völzke,
H.,
Marschall,
P.
y
col.
2008.
Impact
of
fatty
liver
disease
on
health

care
utilization
and
costs
in
a
general
population:
a
5-­-year
observation.
Gastroenterology

134,
85-­-94.

11. Calori,
G.,
Lattuada,
G.,
Ragogna,
F.
y
col.
2011.
Fatty
liver
index
and
mortality:
the

Cremona
study
in
the
15th
year
of
follow-­-up.
Hepatology
54,
145-­-152.

12. Kanuri,
G.,
Bergheim,
I.,
2013.
In
Vitro
and
in
Vivo
Models
of
Non-­-Alcoholic
Fatty
Liver

Disease
(NAFLD).
Int
J
Mol
Sci
14,
11963-­-11980.

13. Bugianesi,
E.,
McCullough,
A.J.,
Marchesini,
G.,
2005.
Insulin
resistance:
a
metabolic

pathway
to
chronic
liver
disease.
Hepatology
42,
987-­-1000.

14. Morino,
K.,
Petersen,
K.F.,
Shulman,
G.I.,
2006.
Molecular
mechanisms
of
insulin
resistance

in
humans
and
their
potential
links
with
mitochondrial
dysfunction.
Diabetes
55
Suppl
2,

S9-­-S15.

15. Kotronen,
A.,
Yki-­-Järvinen,
H.,
2008.
Fatty
liver:
a
novel
component
of
the
metabolic

syndrome.
Arterioscler
Thromb
Vasc
Biol
28,
27-­-38.

16. Savage,
D.B.,
2009.
Postreceptor
insulin
resistance
contributes
to
human
dyslipidemia
and

hepatic
steatosis.
J
Clin
Invest
119,
315-­-322.

17. Gonzalez-­-Baró,
M.R.,
Lewin,
T.M.,
Coleman,
R.A.,
2007.
Regulation
of
Triglyceride

Metabolism.
II.
Function
of
mitochondrial
GPAT1
in
the
regulation
of
triacylglycerol

biosynthesis
and
insulin
action.
Am
J
Physiol
Gastrointest
Liver
Physiol
292,
G1195-­-1199.

18. Yamaguchi,
K.,
Yang,
L.,
McCall,
S.
y
col.
2007.
Inhibiting
triglyceride
synthesis
improves

hepatic
steatosis
but
exacerbates
liver
damage
and
fibrosis
in
obese
mice
with

nonalcoholic
steatohepatitis.
Hepatology
45,
1366-­-1374.

19. Monetti,
M.,
Levin,
M.C.,
Watt,
M.J.
y
col.
2007.
Dissociation
of
hepatic
steatosis
and
insulin

resistance
in
mice
overexpressing
DGAT
in
the
liver.
Cell
Metab
6,
69-­-78.

20. Minehira,
K.,
Young,
S.G.,
Villanueva,
C.J.
y
col.
2008.
Blocking
VLDL
secretion
causes

hepatic
steatosis
but
does
not
affect
peripheral
lipid
stores
or
insulin
sensitivity
in
mice.
J

Lipid
Res
49,
2038-­-2044.

21. Samuel,
V.T.,
Liu,
Z.X.,
Qu,
X.
y
col.
2004.
Mechanism
of
hepatic
insulin
resistance
in
non-­-
alcoholic
fatty
liver
disease.
J
Biol
Chem
279,
32345-­-32353.

22. Samuel,
V.T.
y
Shulman
G.I.
2012.
Integrating
mechanisms
for
insulin
resistance.
Common

threads
and
missing
links.
Cell
148.
852-­-871.

39